Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High-risk CMV D+/R- Transplant Recipients

This publication has 16 references indexed in Scilit:

• Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients
  American Journal of Transplantation, 2004
• Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity1
  Transplantation, 2003
• Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
  Clinical Infectious Diseases, 2002
• Allograft Rejection Predicts the Occurrence of Late‐Onset Cytomegalovirus (CMV) Disease among CMV‐Mismatched Solid Organ Transplant Patients Receiving Prophylaxis with Oral Ganciclovir
  The Journal of Infectious Diseases, 2001
• Cytomegalovirus‐Specific Cellular Immune Responses and Viremia in Recipients of Allogeneic Stem Cell Transplants
  The Journal of Infectious Diseases, 2001
• Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection
  Blood, 2001
• Infection in Organ-Transplant Recipients
  New England Journal of Medicine, 1998
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
  The Lancet, 1997
• Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients
  The Lancet, 1995
• OKT3 Treatment for Allograft Rejection Is a Risk Factor for Cytomegalovirus Disease in Liver Transplantation
  The Journal of Infectious Diseases, 1995